Table 4 Clinical and oncological outcomes of included trials

Anastomotic leakage

7 [31–36, 39, 40]

20

279

33

281

0.68 (0.41, 1.13)

0.14

0%

0.42

Anastomotic stricture

3 [32, 34, 41]

4

165

4

158

0.97 (0.29, 3.25)

0.96

0%

0.19

Pouch-related complications

4 [31, 34, 36, 41]

1

188

4

187

0.50 (0.13, 1.96)

0.32

0%

0.63

Pelvic sepsis

4 [31, 32, 36, 38]

17

151

10

158

1.77 (0.87, 3.59)

0.11

0%

0.84

Intestinal obstruction

4 [32, 36, 38, 41]

13

208

13

209

1.08 (0.53, 2.24)

0.83

0%

0.43

Wound infection

4 [32, 36, 38, 41]

6

208

5

209

1.18 (0.39, 3.62)

0.77

0%

0.84

Rectovaginal fistula

3 [31, 34, 41]

3

145

3

137

0.95 (0.24, 3.79)

0.94

0%

0.42

Urinary complications

3 [32, 34, 36]

8

121

12

128

0.72 (0.31, 1.69)

0.45

0%

0.53

Cardiovascular complications

2 [32, 36]

3

93

2

100

1.55 (0.31, 7.76)

0.59

0%

0.62

Pneumonia

2 [32, 36]

2

93

3

100

0.79 (0.16, 3.85)

0.77

0%

0.51

Mortality (in-hospital/< 30days)

3 [32, 36, 41]

5

189

3

185

1.53 (0.43, 5.45)

0.51

39%

0.20

Reoperations (except stoma reversal)

3 [32, 36, 38]

17

130

25

134

0.74 (0.36, 1.52)

0.41

24.7%

0.27

Relapse (< 2 year)

2 [36, 38]

4

80

4

84

1.05 (0.27, 4.03)

0.947

0%

0.99

Postoperative hospital stay (day)

4 [32, 36, 38, 39]

-

160

-

156

0.42 (− 1.72, 2.56)

0.70

30.5%

0.23